Forest posts 6% sales hike, beating estimates; Indian court won't block Januvia knockoffs;

@FiercePharma: Some good news for Forest Labs: Quarterly sales tick up 6% to almost $800M; Forest credits newer products. More | Follow @FiercePharma

 @CarlyHFierce: Former AstraZeneca exec Tony Zook officially in as new CEO of Vivus. News | Follow @CarlyHFierce

> Forest Laboratories ($FRX) posted a 6% uptick in quarterly sales to $796.9 million, beating analyst estimates; though the company credited its newer drugs, old products also turned in higher-than-expected sales. Report

> An Indian court declined to block Glenmark Pharmaceutical's knockoff versions of Merck's ($MRK) diabetes blockbusters Januvia and Janumet. Report

> U.K. cost-effectiveness watchdogs rejected Roche's ($RHHBY) MabThera as a treatment for a rare type of vasculitis. Report

> Pierre Fabre, founder of the French drugmaker that bears his name, has died at the age of 87. Release

> Belgium's UCB is taking as many as 15 drugmakers to court over their plans to sell copycat versions of its epilepsy treatment Vimpat. Report

> U.S. Vice President Joe Biden met with Indian officials yesterday amid calls from American business leaders to lobby for their better treatment in the country. Report

Medical Device News

@FierceMedDev: Oxford University blood test designed to screen for stress. Item | Follow @FierceMedDev

 @MarkHFierce: Google is the lead in SynapDx's $15.4M funding round - the trial for its autism Dx blood test is now under way. ICYMI yesterday | Follow @MarkHFierce

@DamianFierce: The FDA has changed its approach to medical device hackers, part of its new commitment to cybersecurity. Report | Follow @DamianFierce

> JenaValve lands $62.5M round for heart valve. More

> Baxter wins EU sign-off for $4B Gambro deal. News

> Medical devices help spur Israeli VC investment growth. Article

Biotech News

@FierceBiotech: ICYMI yesterday: First successful transplant of retinas made from embryonic stem cells. Article | Follow @FierceBiotech

 @JohnCFierce: Report: Big Pharma mounts secret attack against data transparency rule (some companies will never learn). ICYMI yesterday | Follow @JohnCFierce

@RyanMFierce: Biogen sees 'unlikely' link between Tecfidera and patient death. Story | Follow @RyanMFierce

> Cytokinetics patches up ALS drug trial after costly study snafu. More

> NYT: GlaxoSmithKline's China R&D audit found ethical breaches. Report

> Array BioPharma scores midstage success for asthma drug. Report

Biotech Research News

 @EmilyMFierce: Novartis MS drug prevents heart failure in animal study. Article | Follow @EmilyMFierce

> Retinas made from embryonic stem cells implanted into mice for the first time. News

> New 3-D model of diabetes target could shape drug design. Story

> Neural origins of menopausal hot flashes discovered. Item

> Revalesio drug alters Alzheimer's progression in animal model. Article

Pharma Manufacturing News

 @EricPFierce: Orphan drugs have become a key product for many companies. See why: Special report | Follow @EricPFierce

> Wockhardt FDA warning letter says QA staff tried to mislead inspectors. Report

> Drug shortages in Ireland getting worse. More

> New bill could free drug user fees from sequestration, improve oversight. Article

> Venus Remedies gets 9 Ukraine plants approved. Item

> AMRI gets issues under control at Burlington plant. Report

And Finally... Scientists search for biomarkers that show how fast people are aging. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.